Latest Administration News

ARN Media reports resilient 2024 financials driven by digital growth and Cody Outdoor contracts, launching a major cost-cutting transformation to sharpen its competitive edge.

Guzman y Gomez has unveiled an ambitious expansion and margin improvement plan at the 2025 Macquarie Australia Conference, reaffirming its FY25 guidance and spotlighting strong franchise growth and operational excellence.

Southern Cross Gold Consolidated has successfully closed the first tranche of a private placement, raising C$88.8 million to advance its Sunday Creek Gold-Antimony Project in Victoria, Australia. The funds will support drilling, resource definition, and early development milestones.

DMC Mining Limited has extended the closing date for its public share offer to August 2025 due to delays in securing exploration licences for its key Guinea projects. The company plans further regulatory updates to accommodate these changes.

Novo Resources reported a reduced net loss of CAD 1.625 million in Q1 2025, progressing exploration with a new aircore drilling program in Western Australia while facing liquidity challenges that cast doubt on its near-term financial sustainability.

Macarthur Minerals is voluntarily delisting from the TSX Venture Exchange and OTC Market to focus on its Australian Stock Exchange listing, aiming to streamline operations and better serve its predominantly Australian investor base.

Aurizon reports a mixed freight volume performance to April 2025 alongside progress on $50 million in annualised cost savings and a potential subordinated hybrid capital raise.

Cardiex Limited has formally lodged its CONNEQT Pulse device with Australia's Therapeutics Goods Administration, marking a critical step toward regulatory approval and market expansion.

Epsilon Healthcare reports ongoing operational challenges post-voluntary administration while unveiling a new pharmacy subsidiary aimed at diversifying revenue streams and rebuilding market confidence.

Conrad Asia Energy has successfully raised approximately A$9 million through a two-tranche placement, with strong insider participation, to fund key milestones in its flagship Mako gas development and other projects.

Neurotech International has reported excellent safety and tolerability for its lead drug NTI164 in 28-day GLP toxicology studies, paving the way for regulatory submissions and longer-term clinical development.

Alterity Therapeutics has secured FDA Fast Track designation for ATH434, its lead candidate for treating Multiple System Atrophy, potentially speeding up regulatory review and bringing hope to patients with this rare neurodegenerative disorder.